New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 13, 2013
13:23 EDTNEPTNeptune increases equity participation in Acasti Pharma
Neptune Technologies & Bioressources announces it has acquired, through the exercise of a previously issued warrant, 6,750,000 Class A common shares in the capital of Acasti Pharma, a majority-owned subsidiary of Neptune. The shares were acquired at a price of CDN$2.30 per Share upon the exercise of the warrant. This reflects a total exercise price of approximately CDN$15.5M. The warrant was delivered to Neptune pursuant to a royalty prepayment agreement, dated December 4, 2012, entered into between Neptune and Acasti, under which Acasti has exercised the option embedded in its exclusive technology license agreement dated August 7, 2008 entered into between Acasti and Neptune to pay in advance all of the future royalties payable under the License Agreement. As a result of the royalty prepayment transaction, Acasti is no longer required to pay any royalties to Neptune under the License Agreement during its term for the use of the intellectual property under license. The exercise of the warrant has increased Neptune's equity participation in Acasti from approximately 57% to approximately 60% as at July 12.
News For NEPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
19:10 EDTNEPTNeptune, Acasti announce USPTO decision that triggers royalty payments
Neptune Technologies & Bioressources (NEPT) and Acasti Pharma (ACST) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, or USPTO, issued a favorable decision, confirming the validity of certain claims in Neptune's '351 patent and triggering royalty payments to Neptune. "This is a significant milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US," said Neptuine CEO Jim Hamilton.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use